Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E, Migkou M, Christoulas D, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Iakovaki M, Panagiotidis I, Ziogas DC, Fotiou D, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: christoulas d. Blood Cancer J. 2016 May 27;6(5):e428. doi: 10.1038/bcj.2016.37. Blood Cancer J. 2016. PMID: 27232930 Free PMC article.
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M, Tsionos K, Dimopoulos MA. Terpos E, et al. Among authors: christoulas d. Ann Oncol. 2010 Jul;21(7):1561-1562. doi: 10.1093/annonc/mdq259. Epub 2010 May 23. Ann Oncol. 2010. PMID: 20497962 Free article. No abstract available.
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Dimopoulos MA, et al. Among authors: christoulas d. Leukemia. 2010 Oct;24(10):1769-78. doi: 10.1038/leu.2010.175. Epub 2010 Aug 26. Leukemia. 2010. PMID: 20739955
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA. Terpos E, et al. Among authors: christoulas d. Ann Oncol. 2012 Oct;23(10):2681-2686. doi: 10.1093/annonc/mds068. Epub 2012 Apr 6. Ann Oncol. 2012. PMID: 22492699 Free article.
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Gkotzamanidou M, Kanellias N, Manios E, Papadimitriou C, Dimopoulos MA. Terpos E, et al. Among authors: christoulas d. Leukemia. 2014 Apr;28(4):928-34. doi: 10.1038/leu.2013.267. Epub 2013 Sep 18. Leukemia. 2014. PMID: 24045498
High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.
Terpos E, Christoulas D, Kastritis E, Bagratuni T, Gavriatopoulou M, Roussou M, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Liakou C, Panagiotidis I, Migkou M, Kokkoris P, Moulopoulos LA, Dimopoulos MA. Terpos E, et al. Among authors: christoulas d. Blood Cancer J. 2016 Oct 7;6(10):e482. doi: 10.1038/bcj.2016.90. Blood Cancer J. 2016. PMID: 27716740 Free PMC article.
Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.
Eleutherakis-Papaiakovou E, Dimopoulos MA, Kastritis E, Christoulas D, Roussou M, Migkou M, Gavriatopoulou M, Fotiou D, Panagiotidis I, Ziogas DC, Kanellias N, Papadimitriou C, Terpos E. Eleutherakis-Papaiakovou E, et al. Among authors: christoulas d. Bone Marrow Transplant. 2017 Nov;52(11):1537-1542. doi: 10.1038/bmt.2017.172. Epub 2017 Aug 14. Bone Marrow Transplant. 2017. PMID: 28805791
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: christoulas d. Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059. Clin Lymphoma Myeloma. 2009. PMID: 19717380
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, Gavriatopoulou M, Anargyrou K, Hamer P, Kastritis E, Carney W, Lipton A. Terpos E, et al. Among authors: christoulas d. Leuk Res. 2010 Mar;34(3):399-402. doi: 10.1016/j.leukres.2009.08.035. Epub 2009 Sep 24. Leuk Res. 2010. PMID: 19781774
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. Dimopoulos MA, et al. Among authors: christoulas d. Eur J Haematol. 2010 Jul;85(1):1-5. doi: 10.1111/j.1600-0609.2010.01432.x. Epub 2010 Feb 20. Eur J Haematol. 2010. PMID: 20192988
71 results